Neogen Co. (NASDAQ:NEOG) CFO David H. Naemura Purchases 14,800 Shares

Neogen Co. (NASDAQ:NEOGGet Free Report) CFO David H. Naemura bought 14,800 shares of Neogen stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average cost of $11.11 per share, with a total value of $164,428.00. Following the acquisition, the chief financial officer now directly owns 61,434 shares in the company, valued at $682,531.74. This trade represents a 31.74 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Neogen Stock Down 0.3 %

Shares of NEOG opened at $11.56 on Friday. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $2.51 billion, a PE ratio of -5.28 and a beta of 1.23. The firm’s 50 day moving average is $13.14 and its 200-day moving average is $14.95. Neogen Co. has a 12 month low of $10.72 and a 12 month high of $18.58.

Neogen (NASDAQ:NEOGGet Free Report) last posted its quarterly earnings data on Friday, January 10th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. The firm had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The company’s revenue was up .7% on a year-over-year basis. During the same quarter last year, the company earned $0.11 EPS. Equities research analysts forecast that Neogen Co. will post 0.5 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on NEOG shares. Guggenheim began coverage on Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target for the company. StockNews.com raised shares of Neogen to a “sell” rating in a research report on Monday, September 30th.

Get Our Latest Stock Analysis on NEOG

Institutional Investors Weigh In On Neogen

Institutional investors and hedge funds have recently bought and sold shares of the company. Inspire Investing LLC increased its holdings in Neogen by 30.9% in the 4th quarter. Inspire Investing LLC now owns 36,383 shares of the company’s stock valued at $442,000 after buying an additional 8,580 shares during the period. Avanza Fonder AB acquired a new stake in shares of Neogen during the 4th quarter worth approximately $169,000. Procyon Advisors LLC increased its stake in Neogen by 22.3% in the fourth quarter. Procyon Advisors LLC now owns 35,513 shares of the company’s stock valued at $431,000 after acquiring an additional 6,467 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in Neogen by 32.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,303,465 shares of the company’s stock valued at $15,824,000 after purchasing an additional 316,457 shares in the last quarter. Finally, Diversified Trust Co lifted its stake in Neogen by 7.1% during the fourth quarter. Diversified Trust Co now owns 74,446 shares of the company’s stock worth $904,000 after purchasing an additional 4,961 shares during the last quarter. Institutional investors own 96.73% of the company’s stock.

Neogen Company Profile

(Get Free Report)

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Featured Articles

Insider Buying and Selling by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.